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INTRODUCTION 
 
 
 Carcinoma breast is the leading cause of death in middle aged women in 
western countries. It is the second most common cancer in females in India. 
However in Metropolitan city like Bombay, the incidence of breast cancer has 
overtaken that of cervical cancer. Information form National Cancer Registry 
show that age adjusted incidence rate was 39.5 per 100,000 females in chandigarh 
for the year 2002 which tops the list. In chennai incidence is about 23.5 per 
100,000 females. Crude incidence rate is 13 per 100,000 females per year. The 
annual mortality rate for breast cancer has been reported to be 4.4 per 100,000 in 
Bombay.  
 
 The number of new cases and number of women dying each year of breast 
cancer is approximately half of that reported from U.S.A. but population of India 
is four times that of U.S.A therefore the breast cancer problem in India is 1/8th of 
that of U.S.A. 
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AIM OF THE STUDY 
1. To study the incidence of carcinoma breast in relation with age and 
socioeconomic status of patients. 
2. To study the relationship of carcinoma breast with menstrual status and  
menstrual history. 
3. To study the relationship of carcinoma breast and use of hormonal pills. 
4. To study the TNM stage at which the patients report to hospital and its 
relation to prognosis. 
5. Relationship of Tumor size to prognosis 
6. To study the relationship between the number of lymph nodes in the axilla 
in relation to prognosis. 
7. Significance of histologic tumour type in relation to prognosis. 
8. Relationship of histologic grade of tumour and prognosis.  
9. Relationship of positive resection margins and prognosis.  
10. To suggest the prognostic factors that can be assessed and routinely 
followed up in carcinoma breast. 
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REVIEW OF LITERATURE 
AGE  
 The incidence of cancer breast increases with increasing age uncommon 
before the age of 20.Cases in woman younger than 30 constitute less than 2% 
while the incidence is about 300 cases per 100,000 in eighth decade of life. The 
cumulative risk of developing breast cancer between the ages of 20 and 40 is 0.5% 
whereas between 50 and 70 is 5 percent. This accounts for the fact that majority of 
patients presenting with breast cancer are over the age of 50 years. 
SEX 
 Male breast cancer constitute less than 1% of the total incidence with 
female to male ratio 1 : 0.01. 
SOCIO ECONOMIC STATUS 
 According to world statistics, cancer breast was more common in women 
with higher socio economic status. 
DIETARY FACTORS 
 Weight correlate with breast cancer risk although causal relationship 
between dietary fat or cholesterol intake has not been demonstrated. Evidence for 
association between alcohol consumption and increased likelihood of developing 
breast cancer is becoming stronger. Relative risk for one unit of alcohol per day is 
1.1 and increases to 1.3 to 1.5 if intake increases to two glasses a day. 
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IONIZING RADIATION  
 An increased risk of breast cancer is noted in woman treated with radiation 
for Hodgkin’s disease, postpartum mastitis. The increased risk becomes apparent 
after a latent period of 10-15 years that effect is most obvious if irradiation occurs 
under the age of 35. 
 
HORMONAL INFLUENCES: 
 Recent studies have confirmed association between excess urinary 
estrogens, frequency of ovulation, age at menarche and increased risk of breast 
cancer. Intrauterine exposure to high concentration of estrogen even increase 
breast cancer risk. Normal breast epithelium possess estrogen and progesterone 
receptors. A variety of growth promoters (TGF , &, EGF, PDGF, FGF) and 
growth inhibitors (TGF – B) are secreted by human breast cancer cells. Many 
studies suggest that they are involved in an autocrine mechanism of tumor 
progression. Production of these growth factors is dependant on oestrogen 
interaction between circulating hormones, hormone receptors on cancer cells and 
autocrine growth factors induced by hormone are involved in breast cancer 
progression. 
 
 Hormonal factors that increase the risk of breast cancer include conditions 
that allow high levels of estrogen to persist for long period of time such as age at 
first menstruation, late age at menopause, parity and age at first birth. 
 5
MENSTRUAL STATUS: 
 
 There appears to be 20% decrease in breast cancer risk for each year that 
menarche is delayed. The relative risk of developing breast cancer for a woman 
with natural menopause before age 45 is half that of a woman whose menopause 
occurs after 55.  
PARITY 
 Nulliparous woman have a relative risk of about 1.4. Anovulatory cycles 
increase risk due to increased exposure to endogenous estrogen in the absence of 
progesterone.  
AGE AT FIRST PREGNANCY 
 The effect of term pregnancy on breast cancer risk varies with age at first 
birth, women whose fullterm pregnancy occurs after age 30 have a two to five fold 
increase in breast cancer risk compared with women having a first full term 
pregnancy before age 18. Breast tissue may undergo differenciation as a result of 
hormonal changes of a full term pregnancy and these differentiated cells are less 
likely to undergo malignant transformation or persisting changes in hormone after 
the proliferative rate of breast epithelium  
LACTATION: 
 A reduction in risk of cancer have been documented but no such effect was 
detected in postmenopausal females. 
OOPHERECTOMY  
  Oopherectomy below 40 years is protective. 
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ORAL CONTRACEPTIVES AND CANCER RISK  
 A 1996 analysis of worldwide epidemiologic data found that women who 
were recent users of birth control pills had a slightly elevated risk of developing 
breast cancer, however. 10 years or more after stopping using OC’S their risk 
returned to same level as if they had never used oral contraceptives.  
 
HORMONE REPLACEMENT THERAPY AND CANCER RISK 
 Two recently published studies compared the risk of breast cancer for who 
had taken estrogen combined with progestin HRT with estrogen only HRT. The 
study focused on nearly 1900 postmenopausal women diagnosed with breast 
cancer and more than 1600 controls matched for age, race. The researches found 
that for combined HRT, the risk of developing breast cancer increased by 24% for 
every 5 years of use. For estrogen only HRT, the risk increased by 6% for every 5 
years of use. 
 
 In addition data from postmenopausal Estrogen / Progesterone Interaction 
trial indicate that about 25% of women who use combination HRT and 8% of 
women with estrogen only HRT have an increase in breast density in 
mammogram. Increased density in mammogram of at least 75% in women of 45 
years or more, is an increased risk for breast cancer. 
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USE OF DES AND BREAST CANCER 
 Current research indicates that the risk of breast cancer in DES exposed 
mothers is approximately 30% higher than the risk in women who have not been 
exposed to DES. This risk stabilizes over time. 
ABORTION AND BREAST CANCER 
 A large scale Epidemiological study reported in New England journal of 
Medicine in 1997, determined that the risk of developing breast cancer for women 
with a history of induced / spontaneous abortion was not different from the risk for 
women without such a history. 
PREVIOUS HISTORY OF BREAST CANCER 
 A history of cancer breast in one side increases the likelihood of a second 
primary cancer in contralateral breast. In many studies the relative risk range 
between 3 and 4. The magnitude of relative risk depend on age at diagnosis of first 
primary breast cancer. For patients younger than 45 risk for contralateral breast is 
five to six times that of general population. In absolute terms the actual risk varies 
between 1% per year in young patients to 0.2% in older patients. 
HISTORY OF BENIGN BREAST DISORDER 
 Patients with history of proliferative disease or atypical ductal or lobular 
hyperplasia have increased risk of developing cancer breast. Relative risk of 
invasive cancer breast based on American college of pathologists consensus 
statement is as follows. 
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NO INCREASED RISK: 
- Adenosis, Hyperplasia, Apocrine metaplasia,  
- Cysts (micro, macro), Duct ectasia, periductal mastitis  
- Fibro adenoma, Squamous metaplasia 
 
SLIGHTLY INCREASED RISK (1.5 – 2 TIMES)  
- hyperplasia (moderate or florid solid or papillary)  
- Papilloma with fibrovascular core  
 
MODERATELY INCREASED RISK 
- Atypical hyperplasia 
The cumulative risk of developing cancer breast in patients with atypical 
hyperplasia was 10% at 55months. A marked interaction between atypia and a 
family history of a first degree relative with breast cancer was found by Dupont 
and Page. The absolute risk of breast cancer development in women with positive 
family history and atypical hyperplasia was 20% at 15 years. 
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FAMILIAL BREAST CANCER: 
 It is estimated that approximately 5-10% of all patients with breast cancer 
may have a germ line mutation of genes BRCA1 and BRCA2. Specific mutations 
of BRCA1 and BRCA2 and more common in women of Jewish ancestry. The 
estimated lifetime risk of developing breast cancer in women with BRCA1 and 
BRCA2 mutations is 40-85% carriers with history of breast cancer have an 
increased risk of contra lateral disease that may be as high as 5 %per year. Male 
carriers of BRCA2 mutations are also at increased risk of breast cancer. Mutations 
of either genes also confer an increased risk of ovarian cancer. In  addition 
mutation carriers may be at increased risk of other primary cancers. High 
penetrance genes are the susceptibility genes located in  
  Long arm of chromosome 17 -> BRCA1 
  Long arm of chromosome 13 -> BRCA2 
 Most of cases of cancer breast in families are due to expression of random 
occurrence rather than due to genetic defect  
So prophylactic mastectomy is limited to cases of 
1. Young patients whose first degree relative had bilateral premenopausal 
breast cancer. 
2. Families with an established genetic defect. 
3. Families with many members affected with a consistent pedigree. 
Syndromes associated with multiple cancers which can run in families include 
 Lynch type II   –  cancer breast and ovary 
 Lifraumeni Syndrome  –  soft tissue sarcomas, brain tumor,   
      leukaemia, melanoma and cancer breast. 
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RISK FACTOR FOR BREAST CANCER 
MAJOR: Gender, Age, Family History, Personal History of contra lateral cancer 
breast, Benign proliferastive changes with atypia, Non invasive carcinoma 
 
MINOR: Early menarche, obesity , Late menopause, Low dose radiation 
CONTROVERSIAL RISK FACTORS  
- Alcohol intake, Smoking, OCP / HRT, Abortion, Diet 
 
PATHOLOGY 
Pathological classification of carcinoma Breast (WHO) 
(I) EPITHELIAL TUMOURS    
 1. Non-invasive 
- Intraductal ca (DCIS) 
- Lobular carcinoma in situ (LCIS) 
2. Invasive. 
a) Invasive ductal carcinoma (not otherwise specified) 
b) Invasive ductal carcinoma (predominant DCIS) 
c) Mucinous  
d) Medullary 
e) Papillary  
f) Lobular 
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g) Adenoid cystic 
h) Secretory 
i) Apocrine 
j) Carcinoma with metaplasia 
(i) Squamous 
(ii) Spindle cell 
(iii) Cartilaginous and osseous  
(iv) Mixed 
k) Others 
LOBULAR 
a) Invasive Lobular carcinoma 
b) Combined Ductal and Lobular.\ 
3. Paget’s disease of Nipple. 
(II) MIXED CONNECTIVE TISSUE & EPITHELIAL TUMOURS 
- Fibroadenoma, carcinosarcoma, phylloides  
(III) MISCELLANEOUS TUMOURS 
- Soft tissue tumours, Skin Tumours, Tumours of 
Hemato poietic, lymphoid tissues 
(IV) UNCLASSIFIED 
(V) MAMMARY DYSPLASIAS 
(VI) TUMOUR LIKE LESIONS  
- Duct ectasia, Inflammatory pseudotumours, Hamartomas 
- Gynaecomastia, Others. 
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DISTRIBUTION OF HISTOLOGICAL TYPES OF BREAST 
CANCER 
1. Insitu Carcinoma  - 15 – 30% 
 DCIS   - 80% 
 LCIS   - 20% 
 
2. Invasive Carcinoma - 70 – 85% 
 Ductal ca (Nos) - 79% 
 Lobular ca  - 10% 
 Colloid  - 2% 
 Medullary  - 2% 
 Papillary  - 1% 
STAGING OF CANCER BREAST 
The American joint committee on cancer (AJCC) 1997 staging system provides a 
strategy for grouping patients with respect to prognosis AJCC has designated 
staging by TNM classification. 
PRIMARY TUMOUR (T) 
 Tx - primary tumour cannot be assessed. 
 To  - No evidence of primary tumour. 
 Tis - Tumour in situ [DCIS, LCIS] or paget’s disease of nipple with no 
   associated tumour. 
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 T1 - 2cm or less in greatest dimension. 
 T1 mic- Microinvasion 0.1 cm or less 
 T1a - 0.1 – 0.5 cm 
 T1b - 0.5 – 1 cm. 
 T1c - 1 – 2 cm. 
 T2 - 2 – 5 cm in greatest dimension 
 T3 - > 5cm in greatest dimension. 
 T4 - Tumour of any size with direct extension to chest wall, skin. 
 T4a - Extension to chest wall (ribs, intercostal muscles, serratus anterior) 
 T4b - edema, peude orange  / ulceration / satellite nodules. 
 T4c - both a & b 
 T4d - inflammatory carcinoma 
 
REGIONAL LYMPH NODES (N). 
 Nx - regional lymph nodes cannot be assessed  
 N0 - No regional lymph node metastasis 
 N1 - Metastasis to mobile ipsilaterral axillary nodes 
 N2 - Metastasis to ipsilateral axillary node (s ) fixed to each other or to 
   other structures  
 N3 - Metastasis to ipsilateral internal mammary nodes. 
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PATHOLOGIC CLASSIFICATION (PN) 
 Pnx - regional nodes cannot be assessed 
 Pno - no regional lymph node metastasis 
 Pn1 - metastasis to mobile ipsilateral axillary nodes  
 Pn1a - only micro metastasis (none > 0.2 cm) 
 Pn1b - metastasis to node > .2 cm 
 Pn1bi - metastasis to 1 – 3 lymph nodes (0.2 – 2 cm) 
 Pn1bii - metastasis to 4 or more nodes (0.2 – 2 cm)  
 Pn1biii- extension of tumour beyond the capsule of a lymph node  
   metastasis less than 2 cm in greatest dimension 
 Pn1biv- metastasis to node > 2cm 
 Pn2 - metastasis to ipsilateral axillary nodes fixed to each other 
 Pn3 - metastasis to ipsilateral internal mammary nodes. 
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DISTANT METASTASIS 
 Mx - presence of distant metastasis cannot be assessed 
 Mo - No distant metastasis 
 M1 - Distant metastasis present (including ipsilateral supra   
   clavicular nodes) 
Stage Grouping 
0 T1s No Mo 
1 T1 No Mo 
IIA 
T0 
T1 
T2 
N1 
N1 
N0 
Mo 
Mo 
Mo 
IIB 
T2 
T3 
N1 
N0 
Mo 
Mo 
IIIA 
To 
T1 
T2 
T3 
T3 
N2 
N2 
N2 
N1 
N1 
Mo 
Mo 
Mo 
Mo 
Mo 
IIIB 
T4 
Any T 
Any N 
N3 
Mo 
Mo 
IV Any T Any N M1 
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MANCHESTER CLASSIFICATION  
Stage I - Tumour confined to breast, skin involvement less than size of  
   tumour. 
Stage II - Tumour confined to breast, with mobile palpable axillary nodes 
Stage III - Tumour extends beyond breast tissue, skin involvement more than  
   size of tumour, fixed to underlying fascia, pectoral muscle  
Stage IV - Growth fixed to chest wall, satellite nodules, fixed axillary nodes, 
   supraclavicular nodes, distant metastasis  
 
SPREAD OF BREAST CANCER 
Carcinoma breast spread by following means 
1. Local spread within the breast 
 By  - direct infiltration along ducts 
  - direct infiltration into breast parenchyma 
  - Breast lymphatics  
 Invades skin, pectoral muscles, chest wall 
2. Regional spread 
 Occurs to axillary and internal mammary nodes. 
 Involvement of lymphnodes is an independent prognostic indicator 
 No histological positive nodes - 80% 5 year survival 
 1-3 histological positive nodes - 50% 5 year survival 
 >4 histological positive nodes - 21% 5 year survival 
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LEVEL OF INVOLVEMENT 
Level I - Lymphnodes lateral to border of pectoralis minor 65% 5 year  
   survival rate 
Level II - Nodes deep to insertion of pectoralis minor 31% 5 year survival  
Level III - Nodes medial to pectoralis minor muscle. 
 
 Lymph passing through either axillary or internal mammary nodes reaches 
the jugulosubclavian venuous confluence. If this is obstructed, lymph passes in 
retrograde way to supraclavicular nodes. 
 
 Lymph channels also cross the diaphragm where they communicate with 
lymphatics of the liver. 
 
3. Spread by blood stream 
  Metastasis occurs to bones, liver, lung, brain, adrenals, ovaries. The 
intercostal veins in addition to draining into azygos, communicate with vertebral 
veins, thus explaining predeliction to axial skeleton. The skeletal metastasis are 
usually osteolytic. Their order of frequency is to lumbar vertebra, femur, thoracic 
vertebra, rib, skull. 
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INVESTIGATIONS 
OBJECTIVE  
1. To confirm diagnosis 
2. To know extent of disease 
3. To use the information in predicting response to certain type of 
treatment. 
A. TO CONFIRM THE DIAGNOSIS : FNAC / BIOPSY 
 FNAC  - To be done in all palpable, suspicious masses 
- Therapeutic in cysts. 
 Sensitivity of breast FNAC performed on palpable masses is reported to be 
90 percent. The specificity and predictive value of breast FNAC approaches 100 
percent because false positive results are rare. 
 Biopsy - Core needle biopsy 
   - Excisional biopsy  
 Can be used for histological grading and ER / PR assay 
NONPALPABLE MAMMOGRAM ABNORMALITY 
1. Needle localized core biopsy under mammographic guidance.  
2. Needle core biopsy directed into lesion under stereo tactic control 
3. USG guided percutaneous biopsy can be done. 
 Image directed needle localization done under local anesthesia. Wire and 
hook passed and positioned in area of calcification density or suspicious area. 
Specimen excised with the wire and radiograph taken to confirm calcifications  
present in biopsy specimen. 
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IMAGING STUDIES  
* Mammography 
  Bilateral study is necessary for screening, diagnosis, follow up. 
 Malignant breast lesions have following characteristics. 
* Irregular Speculated Mass 
* Clustered Calcification  
* Calcification < 0.5mm in diameter 
* Architectural distortion  
* Focal asymmetric density. 
BENIGN BREAST LESIONS 
* Solid or lucent centered spheres 
* Smooth, round calcifications 
* Calcifications > 1mm 
B TO KNOW ANATOMICAL EXTENT OF THE DISEASE 
1. X RAY CHEST 
 To rule out pulmonary metastasis  
2.  USG ABDOMEN 
 To rule out liver metastasis, free fluid retroperitoneal  lymphadenopathy 
3. BONE SCAN 
 In stage I and II incidence of skeletal metastasis is 2-6% 
 In stage III it is 14% 
 Bone scan has a lead of 6-18 months over radiograph in demonstrating 
metastasis. 
 
 
 
 Most bony metastasis appear 20 months to. 4 years after mastectomy 
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 Bone scan indicated in higher stage of disease, in patients who have bone 
pains, raised level of serum alkaline phosphatase, positive skeletal radiogram, 
palpable regional or metastatic disease. 
 
4. CAT and MRI 
 They aid in evaluating axilla, mediastinum, supraclavicular area for 
adenopathy. 
  MRI helps to evaluate patients after prosthetic implants. To diagnose 
recurrence after surgery. It is often difficult to predict whether it is local 
recurrence or fibrosis or scarring. In MRI the scar tissue will not be enhanced with 
contrast media whereas the tumour (recurrence) is seen as enhanced area. 
 
 
C. TO USE INFORMATION IN PREDICTING RESPONSE TO 
CERTAIN TYPES OF TREATMENT 
 
 A strong correlation exist between presence of ER and PR receptors and 
response to endocrine therapy, all tissues should be analyzed for receptors 
whenever adequate volumes are available more than 60 percent of ER positive 
tumours will respond to adjunctive endocrine therapy. 
 Two types of assays are used to quantitate ERS and PRS 
I. For ligand binding methods (eg. Dextran coated charcoal assay) results are 
expressed in femtomoles of receptor protein per milligram of cytosol 
protein (Fm01 / mg) cut offs vary form 3 – 20 Fmol / mg. Specimens 
should be large and  must be immediately fixed in liquid nitrogen results of 
this method may be  affected by presence of estrogen / tamoxifen in the 
specimen. 
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II. With regard to monoclonal antibody – based methods (eg. immunohisto 
chemistry  IHC, enzyme immuno assay)  IHC has 2 advantages. First, it 
can be performed on any type or size of specimen, including cell blocks 
from body fluids or those  fixed or embedded in paraffin section, it 
measures total protein, therefore it is not  affected by presence of estrogen / 
tamoxifen.  
 
HER2 / NEU. STATUS 
A. IHC methods are used to assess HER2 / neu status. This method is a 
semi quantitative assay using monoclonal antibody. 
B. Scoring of HER2 / neu over expression using DAKO Hercep test. 
• Strong complete membrane staining in more than 10% of tumour 
cells – strongly positive –score of 3+. 
• Weak to moderate complete membrane staining in more than 10% of 
cells – weakly positive –score of 2+. 
• Faintly perceptible membrane staining in more than 10% of tumour 
cells – interpreted as negative – score of 1+. 
• No staining or staining in 10% of tumour cells – Negative score of 0. 
• Detection of gene amplification with fluorescence in situ 
hybridization (FISH) is highly specific and has 82% overall 
concordance rate with IHC. 
 HER2 / neu over expression is associated with poor prognosis 
 Taxanes seem to have high efficacy in patients overexpresing HER2 
(relative risk 65%) Compared with HER2 / negative group (35%) 
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MANAGEMENT 
 
 In the management of carcinoma breast, cure should take precedence over 
cosmesis without disregarding it. Management falls into 2 main categories. 
- Loco regional control 
- Systemic 
I. SURGICAL MANAGEMENT 
 A century ago William Hallstead published his first report on radical 
mastectomy for control of breast cancer. At that time this was considered as 
appropriate solution to the problem. Later review showed that long term rates were 
not changed despite dramatic reduction in local recurrence rate. 
 
 Fisher stated that venous lymphatic communication exist and that particles 
injected into lymphatic drainage of breast rapidly appeared in venous circulation. 
Hence the disease was considered to be systemic long before clinical diagnosis 
was made. Fisher hypothesis indicated that variation in local and regional 
treatment were unlikely to influence  long term cure. A systemic therapy would be 
necessary from the beginning which led to clinical trials of adjuvant systemic 
therapy 
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 Different surgical procedures available are  
 
1) RADICAL MASTECTOMY 
  Here the breast, pectoralis major, regional lymphnodes along axilla 
upto  costoclavicular ligament are resected. 
2) EXTENDED RADICAL MASTECTOMY 
  Here in addition to the above, internal mammary nodes are also 
removed. 
3) MODIFIED RADICAL MASTECTOMY 
  Pectoralis major is left intact  
 (i) Patey’s   Modification  
Pectoralis minor is removed and level I, II, III Lymph nodes are removed. 
(ii) Scalon’s Modification 
  Pectoralis minor divided level I, I, III Lymph nodes are removed. 
(iii) Auchincloss Modification  
 Pectoralis Minor is left intact level I / II nodes are only removed. 
4) BREAST CONSERVING SURGERIES  
 (i) Wide local excision (lympectomy, tylectomy, segmental or  partial 
    mastectomy)  
  Lump with 1 cm margin of grossly normal breast tissue is removed 
(ii) Quadrantectomy 
Quadrant of breast with lesion is removed. 
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5) SKIN SPARING MASTECTOMY 
  Skin envelope is preserved while removing nipple areola complex, 
all  underlying breast & axillary contents followed by immediate reconstruction 
with  TRAM Flap or Expandable implants with small graft at areola site. 
6) SIMPLE OR TOTAL MASTECTOMY 
  Breast, Axillary tail of Spence and lymphnodes along it (low anterior 
group) are removed. 
AXILLARY DISSECTION 
 The axillary lymphnodes should be staged to aid in determining prognosis 
and therapy. Data suggest that the level of lymphnode involved does not add 
independent prognostic information to the total number of positive axillary nodes. 
Therefore only level I and II dissection therapy removing a satisfactory no: of 
nodes for evaluation while reducing morbidity from the procedure can be adopted.  
 In 918 patients with T1 lesions reported by silver stain et al incidence of 
axillary metastasis was 23%. 
 Factors identified as predictors of axillary lymph node metastasis were 
tumour size, grade, tumor palpability. 
 Steele et al reported sampling 3 or 4 ALNS provides accurate assessment of 
axilla with false negative rate of 10%   
3 methods used are: 
1) Axillary lymph node dissection 
2) Axillary node sampling. 
3) Sentinel lymph node biopsy  
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 Sentinel node is defined as the first node of lymphatic basin that receives 
primary lymphatic flow. Identification of SLN done by injection of technetium 
labeled sulfur colloid, vital blue dye or both in 92-98% of patients. The reports 
demonstrate 97.5 to 100% concordance between sentinel lymph node biopsy and 
complete axillary lymph node dissection.  
 
BREAST RECONSTRUCTION 
It has become an integral part of management of breast cancer. 
 It may either be done immediately following surgery or after 6 months. 
Various techniques available are  
1) Implants or expanders. 
2) Autologous tissue 
(i) pedicled flap 
(ii) free flap. 
3) Combination of both. 
 
SUB PECTORAL IMPLANTS  
 Involves placement of a tissue expander subpectorally and creating the 
breast mound by repeated expansion introducting saline and later placement by a 
permanent implant. Modern breast implants are manufactured with an outer shell 
of polydimethyl siloxane (silicone) and contains a filler material such as silicone 
gel to give its volume. 
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DISADVANTAGE  
 1) Leakage of silicone gel into surrounding tissue 2) Capsule Contracture. 
AUTOLOGOUS FLAPS 
  They are more complex, expensive procedures requiring comprehensive 
training and experience. 
TRAM FLAP 
 Based on a transversely sited lower abdominal island of skin and fat 
supplied by perforators from superior and inferior epigastric vessels. It results in a 
soft natural and ptotic breast and avoids the need for additional prosthetic volume 
replacement. 
 DISADVANTAGE: 
 Flap loss, abdominal herniation and abdominal weakness. Free flap 
circulation is by performing micro vascular anastomosis between inferior 
epigastric and thoraco dorsal or internal mammary vessels.   
 Lattismus dorsi flaps can be used to reconstruct irradiated tissues. 
II. RADIOTHERAPY 
 It is now proved that radiation therapy not only improves local control of 
breast cancer but along with surgery and chemotherapy improves the probability 
of survival. 
 A number of studies have examined the value of adding postoperative RT 
to adjuvant chemotherapy and important ones are. 
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1) British Columbia trial 
2) Denmark trial. 
 In both trials, RT resulted in large reduction in local recurrence. The 7 years 
survival rate for premenopaused patients was 62% with RT compared with 55% 
without RT. 
Two main types of techniques  
a) Whole breast irradiation 
  Done following breast conservation surgery. 
b) Loco regional RT technique 
  Breast or chest wall, ipsilateral axilla, supra and infra clavicular 
lymph nodes region, internal mammary chain of nodes are irradiated. 
 
INDICATIONS FOR CHEST WALL IRRADIATION  
1) Positive margin or gross residual disease. 
2) T3 tumour, especially with positive node. 
3) T4 tumour 
4) Four or more positive axillary lymph nodes. 
5) Close surgical margin (< 2cm) 
6) Following breast conservation  therapy. 
 
INDICATIONS FOR AXILLARY IRRADIATION  
1) 4 or more axillary lymph nodes positive. 
2) Extra nodal disease. 
3) Inadequate axillary sampling. 
4) More that 50% of lymph nodes positive. 
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OPTIMAL RADIATION THERAPY TECHNIQUE AND DOSES. 
 Following excision of primary tumour and lymph node dissection, radiation 
is delivered to entire breast for a total of 4500 to 5000 CGY over 4.5 to 5.5 weeks 
100 – 200 CGY / day followed by supplemental  boost of 1000 to 1600 CGY. 
SIDE EFFECTS 
 - Fatigue, Skin erythema, Dry and moist desquamation, Arm Edema  
 - Shoulder discomfort  
 - Progressive Parasthesia / weakness of arm, hands 
 - Radiation pneumonitis 
 - Radiation induced soft tissue sarcoma, osteosarcoma angiosarcoma. 
 - Bronchogenic carcinoma in ipsilateral lung in smokers. 
III. CHEMOTHERAPY 
 Chemotherapy is given to all premenopausal women with positive nodes. 
Chemotherapy has been shown to prolong disease free and overall survival in 
premenopausal patients with stage II breast cancer, both in randomized clinical 
trials and in population  based studies. 
 It is started once surgical wound is healed. 
INDICATIONS 
1) Premenopausal patients with positive nodes. 
2) Patients with hormone receptor – negative tumors 
3) Patients with visceral metastasis 
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Commonly used Chemotherapeutic agents in breast cancer 
Regimen Dose / schedule Interval days Cycles 
CMF (standard) 
Cyclophosphomide  
 
Methotrexate 
5-flurouracil 
 
100mg / m2 /d po for 14 day 
40mg / m2 / d IV days 1 and 8 
600mg / m2 /d IV days 1 an 8 
28 6 
CMF (IV, node 
negative patients) 
Cyclophosphomide 
methotrexate  
5-flurouracil 
 
 
600mg / m2 IV 
40mg / m2 IV 
600mg / m2 IV 
21 12 
CAF  
Cyclophosphomide  
 
Adriamycin 
5- flurouracil 
 
100mg / m2 /d Po for 14 days 
30mg / m2 /d IV 1 and 8 
500mg / m2 /d IV 1 and 8 
28 6 
CAF 
Cyclophosphomide  
Doxorubucin 
5- flurouracil 
 
600mg / m2 IV day 
60mg / m2 IV day 
600mg / m2 / d IV day 
21-28 4-6 
 
 
 
ADJUVANT HARMONE THERAPY 
TAMOXIFEN  
 Tamoxifen a selective ER modulator that inhibits the action of estrogen at 
estrogen receptor, has been preferred adjuvant agent in breast cancer prevention 
for more than 20 years. The drug has been shown to produce 47% reduction in risk 
of relapse after 5 years of treatment and 36% reduction in proportional risk of 
death at 10yrs.Tamoxifen is given to post menopausal women with positive 
hormone receptor assay. It is given in the dose of 20mg daily for 5 years. 
SIDE EFFECTS 
 Alopecia, Bone Marrow suppression, Immuno suppression, Nausea / 
vomiting, Cardio toxicity 
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SIDE EFFECTS 
 Flushing, Vaginal dryness, Weight gain, Endometrial cancer, 
Thromboembolism 
GUIDELINES FOR CHEMO / HARMONAL THERAPY 
Node Positive Premenopausal Postmenopausal 
ER / PR + ve 
 
ER / PR - ve 
Combination chemo therapy + 
Tamoxifen  
CCT 
Tamoxifen   ± CCT  
 
CCT ± Tamoxifen 
Node Negative   
Favorable tumour character  
unfavorable  
Tamoxifen 
CCT 
Tamoxifen 
Tamoxifen 
Favorable : Size < 2cm. ER / PR + ve, histological grade I,II. 
Unfavorable : Size > 2cm. ER / PR – ve, histological grade III. 
 
AROMATASE INHIBITORS 
 The third generation aromatase inhibitors anastrezole letrozole, exemestane 
are superior to tamoxifen in postmenopausal women with metastasis ER breast 
cancers. MA17 trial demonstrated reduction in risk of recurrent breast cancer, 
reduction in development of contra lateral breast cancer improvement in overall 
survival in women with positive nodes and have received aromatase inhibitors.  
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DRUG /  DOSAGE ADVERSE EFFECT 
Anastrozole 1 mg / d Hot flushes, fatigue, vaginal dryness 
nausea, diarrhoea headache, osteoporosis, 
rarely DVT, MI Stroke.  
Exemestane 2.5 mg / day Hot flushes, nausea, fatigue Sweating, 
decreased Bone mineral density, 
lymphocytopenia  
Letrozole 2.5 mg / day Hot flushes, arthalagia, myalgia, faligue 
dizziness osteoporosis decreased bone 
mineral density rarely M.I, stoke. 
 
TRASTUZUMAB  
 Approximately 25% of patients with carcinoma breast have tumours that 
overexpress her2 / neu. 
 
 Trastuzumab is a monoclonal antibody that binds to HER2 / neu receptor. 
Added to chemotherapy this drug has reduced the risk of recurrence by 50% and 
prolonged survival by 20% in a 3 years study. 
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PROGNOSTIC FACTORS IN BREAST CANCER 
A. COMMONLY ASSESSED 
1. Number of involved lymphnodes in axilla 
2. Tumour size 
3. Tumour TNM Stage 
4. Lymph vascular invasion 
5. Histologic Tumour type 
6. Histologic Grade 
7. Nuclear grade 
8. Sex steroid receptor 
9. Ploidy 
10. Proliferative indices.       
 (S Phase fraction, Thymidine labeling index, mitotic index) 
 
B. INVESTIGATIONAL 
1. Proliferative indices  
  (Ki67, PCNA / Cycline, M1B1) 
2.  His tone H3 
3. Transforming growth factor (a,b). 
4. Epidermal growth factor 
5. Insulin like growth factor. 
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6. Once gene products (HER2 / neu or cerb B2, C-myc, ras) 
7. P53 Protein 
8. Invasion related markers 
  (Cathepein D, Stamelysin 3, Laminin receptor)  
9. Angiogenesis factors (PS2, heat stock protein, MDRI) 
I. TUMOUR SIZE 
 < 2 cm – favorable 
 > 2 cm – Bad prognosis 
II. LYMPHNODES STATUS  
No histological involvement  - 80% 5 year Survival  
1-3 positive Lymphnodes - 50% 5 year Survival  
> 4 positive Lymphnodes - 21% 5 year Survival  
III. Tumour Type 
Mucinous Papillary, Tubular, medullary - favourable prognosis   
IV. TUMOUR GRADE 
 Based on bloom and Richardson grading includes. 
- Tendency to form tubules 
- Pleomorphism 
- Hyper chromatic nuclei and mitotic figures  
 Grade I, II - good prognosis  
 III  - poor prognosis 
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POINTS 
TUBULAR 
GRADE 
NUCLEAR 
GRADE 
MITOTIC INDEX 
1. Well differentiated 
if tubular structures 
occupy more than 
75% of tumour 
Small, uniform 
staining nucleus 
Low (.0-3.3 / mm2) 
2. Tubular structures 
represent 10 –75% 
of tumour 
Moderate variation 
in nuclear size and 
shape 
Medium(3.3-7/mm2)
3. Tubular structures 
represent less than 
10% of tumour 
Marked nuclear 
pleomorphism with 
dark staining 
High > 7/mm2 
 
Well differentiated cancer - 3-5 Pts  - GRADE I 
Moderately differentiated - 6-7 Pts  - GRADE II 
Poorly differentiated - 8-9 Pts – GRADE III 
V. HORMONAL STATUS 
 ER / PR Positive  - Good prognosis 
VI. HER-2 NEU 
 Over expression of HER-2 neu  - poor prognosis 
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A) RISK FACTOR BIOMARKERS 
 Include familial clustering, inherited germ line abnormalities proliferative 
breast disease with atypia, mammographic densities. 
B) EXPOSURE BIOMARKERS 
 Include measurement of carcinogen exposure such as DNA adducts. 
C) DRUG. EFFECT BIOMARKERS 
 Serum glutathione reductase activity, ornithine decarboxylase activity used 
to monitor biochemical effect of durgs. 
D) PROGNOSTIC BIOMARKERS 
A)  INDICES OF PROLIFERATION  
  PCNA is a nuclear protein associated with DNA-Polymerase whose 
expression increases in G1 phase of cell cycle and its expression correlates with 
high S phase fraction, aneuploid, high mitotic index, high tumour grade. 
B) INDICES OF ANGIOGENESIS  
  Angiogenesis is necessary for growth invasiveness of breast cancer. 
VEGF (Vascular Endothelial Growth Factor) over expression is correlated with 
recurrence in node negative breast cancer. 
a) P53: 
  P53 plays central role in cell cycle arrest, DNA repair and 
programmed cell death. P53 over expression correlates with high nuclear grade, 
high preliferative fraction, aneuploidy, hormone receptor negative status. 
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  At the university of Alabama at Birmingham, analysis of molecular 
biomarkers of breast cancer prognosis was undertaken. It was found that 
combination of HER/2 neu and P53 over expression more accurately predicted 
disease free and overall survival than clinico pathological factors 
 
OVERVIEW OF BREAST CANCER THERAPY 
I. CARCINOMA – IN SITU (STAGE 0) 
1) DCIS involving two or more quadrants require mastectomy. 
2) Limited disease – lumpectomy + radiation therapy 
3) Low grade DCIS, < 0.5cm – Lumpectomy alone 
4) Nonpalpable DCIS – Needle localization and surgical resection 
 Adjuvant tamoxifen considered in all patients women treated with 
mastectomy have local recurrence of less than 2% mortality < 2%. 
 Women treated with lumpectomy and radiotherapy had local recurrence 
rate of 9% mortality 2%. 
 Recurrence occurred when tumor size is more than 2.5 cm, DCIS was of 
comedo type. 
 
LCIS 
  Since LCIS is considered a marker for increased risk rather than precursor 
of invasive disease, current treatment is observation with or without tamoxifen. 
The goal of treatment is to prevent or detect at an early stage the invasive cancer 
that develops in 25 to 35% of patients. There is no benefit to excising LCIS, as the 
disease diffusely involves both breast and the risk of invasive cancer is equal for 
both breast. 
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VAN NUYS PROGNOSTIC INDEX FOR DCIS 
Score Size Margin of excision Grade 
1. < 1.5 cm > 0.9 cm Non high grade, no necrosis  
2. 1.5 – 4 cm 0.1 – 0.9 cm Non high grade with necrosis 
3. > 4 cm < 0.1 cm High grade with or with out necrosis 
 3 – 4 -> small low grade lesions treated by excision alone. 
5 – 7 -> Excision + Radiation 
8 – 9 -> Mastectomy  
III. EARLY BREAST CANCER 
Includes stage I, II A, II B 
SURGICAL TREATMENT 
1) Breast conserving therapy including 
  Lumpectomy, breast irradiation, surgical staging of axilla 
2) Modified Radical mastectomy 
 
ADJUVANT RADIATION THERAPY  
 4 or more nodes positive  
ADJUVANT CHEMOTHERAPY  
 All nodes positive cancers 
 All node negative cancers with adverse prognostic factors like high nuclear 
histologic grade, negative hormone receptor status. 
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CONTRAINDICATION TO BREAST CONSERVATION SURGERY  
1) Multicentric disease 
2) Prior radiation therapy  
3) Positive surgical margins  
4) Contraindication for radiotherapy 
5) Connective tissue disorder 
III. LOCALLY ADVANCED BREAST CANCER 
(STAGE III A / III B) 
A) Operable disease (Stage III a) 
Modified radical mastectomy, followed by adjuvant chemotherapy, 
followed by radiotherapy. 
Chemotherapy  - maximize distant disease free survival 
Radiotherapy  - maximize loco regional disease free survival  
B) In selected stage III a patients 
Neo adjuvant chemotherapy is used to reduce size of primary cancer and 
permit conservation surgery  
C) Inoperable stage III A / III B   
Neo adjuvant chemotherapy is used to decrease loco regional tumour 
burden permitting subsequent surgery followed by adjuvant chemo and 
radiotherapy. 
IV. METASTASIC DISEASE (STAGE  IV) 
 Treatment for stage IV disease is mainly to enhance a woman’s quality of 
life. 
HORMONE THERAPY 
 Given in women with hormone receptor positive cancers, women with bone 
soft tissue metastasis only, women with limited   asymptomatic visceral metastasis 
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SYSTEMIC CHEMOTHERAPY 
INDICATIONS  
1) Women with hormone receptor negative cancer 
2) Symptomatic visceral metastasis. 
3) Hormone refractory metastasis. 
 
SURGERY  
 Mastectomy for fungating breast cancer, Pleural effusion, Pericardial 
effusion,  
Pathologic fracture, Spinal cord compression   
RADIATION THERAPY  
 Painful bony metastasis, Unresectable CNS metastasis, Painful chest wall 
lesions Biphosphnoates can be given in addition to chemotherapy in women with 
bone metastasis  
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FOLLOW UP 
 
 American society of clinical oncology recommendations for breast 
cancer follow up care. 
1. All patients should learn correct method of breast self examination and 
 should practice it every month. 
2. Follow up for first 2 years: visit at 3 months interval 
 At 3 monthly interval : history, physical examination 
 At 6 monthly interval : blood count and biochemistry, USG abdomen  
     mammography  
 At yearly interval : chest X ray, pelvic examination and pap smear,  
     mammography  
Follow up for Next 3 years  : visit at 6 months interval 
 At 6 monthly interval: history, physical examination 
 At yearly interval : blood count and biochemistry, USG abdomen  
     mammography chest X ray,    
      pelvic examination and pap smear.   
Follow up for Next 5 years  : visit at 1 year interval 
 At yearly interval : history, physical examination 
 At 2 yearly interval : blood count and biochemistry, USG abdomen  
    mammography chest X ray,    
    pelvic examination and pap smear.  
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BREAST CANCER PROGNOSIS 
5 years survival rate for  
 Stage I  94%   III A  52% 
 Stage II a  85%  III B  48% 
 Stage II b  70%  IV  18% 
MALE BREAST CANCER 
1) Accounts for less than 1 % of all breast cancer 
2) Occur in sixth decade of life. 
3) It is preceded by gynaecomastia in 20% of men. 
4) 85% is of infiltrating ductal carcinoma variety. 
 There is early involvement of pectoralis major and chest wall 80% are 
hormone receptor positive. 
TREATMENT 
 Modified radical mastectomy / Radical mastectomy when muscle is 
involved is the treatment of choice with postoperative radiotherapy and adjuvant 
CMF  in node positive males. 
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MATERIALS AND METHODS 
 
 This is a Study of 95 Cases of Cancer Breast diagnosed and treated at 
Thanjavur Medical College Hospital over a period of 15 Months from September 
2005 to December 2006. 
 
 About 112 patients with cancer breast were admitted during this period of 
which 17 patients were operated and referred for further management from Trichy, 
Karaikal and elsewhere, they were excluded from the study. 
 
 At presentation a detailed history was taken and clinical examination done. 
Diagnosis was confirmed histologically and investigations like Blood 
Biochemistry, chest X-ray, ultrasound abdomen were also done to stage the 
disease. In patients presenting with locally advanced breast disease or metastatic 
disease investigations like CT abdomen, CT chest, mammogram of opposite 
breast, pleural fluid and ascitic fluid cytology were done. 
 
 The modality of treatment was decided based on stage of disease at 
presentation and operability. Most of the patients with early breast cancer II A, II 
B, III A underwent modified radical mastectomy.  
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 Patients with locally advanced breast cancer were subjected to simple 
mastectomy or simple mastectomy with axillary sampling and all these patients 
were also given radiotherapy and chemotherapy. Patients with Metastatic disease 
received chemotherapy and radiotherapy. 
 
 All cases were followed up at monthly interval with clinical examination, 
blood count and biochemistry, ultrasound abdomen, chest X ray, Mammography 
was done at 3 monthly interval during the follow up period. Data obtained were 
recorded in a specific proforma and analysed in systematic way. 
 
LIMITATIONS OF STUDY 
 Due to nonavailability of immunohistochemical studies, in our hospital 
prognostic markers like ER, PR receptors Her 2 neu receptors were not included as 
routine in this study group. They were done only for affordable patients that is for 
18 patients.     
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OBSERVATION AND DISCUSSION  
 
 All histologically proven cases of cancer breast presenting with lump, 
ulcer, discharge, metastatic symptoms were included in the study. 
 
EXCLUSION CRITERIA 
 17 patients who where operated and referred for further management from 
Trichy, Karaikal and else where were excluded from the study. 
 
SEX 
 Only < 1% of cases of cancer breast occurred in men. In our study only two 
patients were male. One had invasive intraductal carcinoma and was treated with 
modified Radical mastectomy and other had malignant fibrous histiocytoma with 
lung metastasis during presentation treated with chemotherapy. They account for 
2.10%. 
 
AGE 
 Incidence of breast cancer increases with age. In U.S lifetime risk of 
developing breast cancer is 12.2% or 1in 8 women. The age-adjusted incidence of 
breast cancer shows increase in incidence to 4% between 1980 and increase 
occurred primarily in women aged 55 yrs or older.  
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In our study. 
 
Age Group (years) 
 
 
No. Of Patients 
 
 
Percentage 
 
< 30 2 2.10% 
30-40 22 23.14% 
40-50 45 47.36% 
50-60 22 23.14% 
60-70 4 4.21% 
 
Youngest age was 24 years. 
Oldest age was 65 years. 
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Most of our patients were between 40 – 50 years.  
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FAMILY HISTORY 
¾ The relative risk of developing breast cancer is 1.7 to 2.5 in women with a 
history of breast cancer in a first degree relative,1.5 with an affected second 
degree relative. About 5% of breast cancers appear to have inherited gene 
mutations that are dominant and highly penetrant. 
¾ In our study there was no significant family history. 
  
SOCIOECONOMIC STATUS 
 Cancer breast is more common in women of higher socioeconomic 
status, but in our study most of the patients belonged to lower 
socioeconomic status.  
 This can be explained by the fact that most of the people utilizing the 
health services of this institution are from lower socioeconomic 
group. 
DIETARY FACTORS 
 Epidemiological studies of fat consumption and cancer risk have produced 
inconclusive results. But however weight does correlate with breast cancer risk. 
Multiple studies demonstrate a relative risk of 1.4 for each 24 Grams of alcohol 
(about two drinks) consumed  
 In our study all were taking mixed diet. None of them consumed alcohol. 
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(IONISING RADIATION) ENVIRONMENTAL FACTORS 
 Radiation exposure after age 40 produces minimal increase in risk. Risk 
reported in women receiving mantle radiation for treatment of Hodgkin’s disease 
before 15 years of age. Other environmental factors including exposure to 
electromagnetic fields and organochlorine pesticides have been suggested to 
increase breast cancer risk. 
 In our study none gave history of previous radiation 
MENSTRUAL STATUS 
 Increased exposure to endogenous estrogen peaks during menstrual cycle 
and predisposes to cancer breast. There appears to be 20% decrease in breast 
cancer risk for each year that menarche is delayed.  The relative risk of developing 
breast cancer for a women with natural menopause before age 45 is half that of a 
woman whose menopause occurs after 55.oopherectomy before 50 years decreases 
breast cancer risk.  
¾ In our study 3 patients attained menarche before age of 12 and 6 attained 
menopause after 55 years 4 underwent total abdominal hystrectomy with 
bilateral salphingo opherectomy for co.existing gynaecological problems 
like dysfunctional uterine bleeding, fibroid 
¾ 45 patients were premenopausal 47.36% 
¾ 44 Patents were postmenopausal 46.31% 
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PARITY 
¾ Nulliparous have a relative risk of about 1.4.  
¾ In our study 5 patients were nullipous which was about 5.26%. 
 
AGE AT FIRST PREGNANCY 
 First full term pregnancy after age 30 have a twofold to fivefold increase in 
breast cancer risk compared with women having a first full term pregnancy before 
age 18 or 19. In our study 9 patients had their first child above the age of 28 years. 
 
LACTATION 
 Protective effect of breast feeding is hard to assess as it is difficult to 
differentiate from the effects of pregnancy. Recent data indicate independent 
protective effect of breast feeding although not all studies confirm this finding. 
  In our study 3 patients had not breast fed their children. 
ORAL CONTRACEPTIVE PILLS  
 Relative risk of developing breast cancer while taking oral contraceptives is 
1.24. On stopping therapy risk diminishes to 1.01 over ensuring 10 years. 
HORMONE REPLACEMENT THERAPY  
 Estrogen replacement therapy increases relative risk by 1.8 for use of 5 
years or less and 2.65 for longer than 5 years.  
 In our study none of the patients had used either OCP/HRT. 
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PREVIOUS HISTORY OF BENIGN BREAST DISEASE/BREAST 
CANCER 
 Nonproliferative disease is not associated with increased risk of breast 
cancer. Prolifertive disease without atypia results in small increase in relative risk 
1.5 to 2.0 Atypical hyperplasia is associated with relative risk 4 to 5. 
 
Study 
Relative risk 
nonproliferstive 
Proliferstive 
without atypia 
Atypical hyper plasia 
nashville 1 1.9 5.3 
Florence italy 1 1.3 13 
Ourstudy 3 cases 4 cases 3 cases 
 
3 presented with Atypical hyperplasia  
3 – fibroadenoma (Nonproliferative) 
4 – Sclerosing fibroadenosis (Proliferative without Atypia)   
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CLINICAL PRESENTATION 
• In our study clinical presentation were as follows 
 
 NO. OF PATIENTS PERCENTAGE 
Painless lump 52 54 
Lump with pain 24 25.24 
Lump with ulcer 3 3.14 
Nipple discharge 12 12.63 
Metastatic symptoms 4 4.21 
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Most of the patients present with painless lump  
1 – Presented with weakness of lower limb  
1 – Presented with Seizures  
2- dyspnea  
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SITE OF INVOLVEMENT 
• Commonest site involved in ca breast is upper outer Quadrant. 
In our study it was as follows. 
 
SITE NUMBER PERCENTAGE 
Upper outer 54 56.84% 
Upper inner 12 12.63% 
Lower outer 4 4.21% 
Lower inner 4 4.21% 
Central 12 12.63% 
All 9 9.46% 
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TUMOR SIZE AND PROGNOSIS 
SIZE IN (CMS) NUMBER PERCENTAGE 
<2 1 1.05% 
2-5 25 28% 
>5 64 71% 
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Increased tumor size is associated with early local recurrence, 5 cases who had 
local recurrence in our study had tumor size more than 8 cm during presentation. 
Four patients with lung metastasis had tumor size more than 8 cm  
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LYMPHNODE INVOLVEMENT 
No. of nodes No. of patients % 5 years survival 
Nil 29 31% 80% 
<3. 54 57% 50% 
>3 12 12% 21% 
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69 patients show clinically positive lymphnodes  
21are node negative 
3 – had bilateral axillary nodes 
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More than 3 nodes were positive in 12 of our patients 
Of which one patient presented with lung metastasis 4 patients developed local 
recurrence during follow up  
3 had opposite axillary node involvement during follow up  
3 had supraclavicular node involvement 
One patient with supraclavicular node involvement developed liver metastasis 
 
STAGE AT PRESENTATION 
 
STAGE NUMBER PERCENTAGE 
Carcinoma in situ 1 1.05 
II A 9 9.47 
II B 22 23.15 
III A 26 27.36 
III B 33 34.73 
IV 4 4.21 
 
Most of the patients presented in stage III that is 62.09% for which 5 year survival 
rate is only about 41%. 
 
 
 
 
 55
1%
9%
23%
28%
35%
4%
0%
5%
10%
15%
20%
25%
30%
35%
P
ER
C
EN
TA
G
E 
O
F 
P
A
TI
EN
TS
Ca in situ II A II B III A III B IV
STAGE
STAGE AT PRESENTATION
  
 
2 patients who later developed lung metastasis where of stage III B 
one patient developed liver metastasis. 
3 patients later developed local recurrence 
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PATHOLOGICAL TYPES 
• According to world statistics Invasive ductal carcinoma account for 85 % to 90% 
of all breast cancers 
In our study Pathological varieties encountered were as follows. 
 
TYPE NUMBER OF CASES PERCENTAGE 
Invasive ductal carcinoma  83 87.36% 
Ductal carcinoma in situ 1 1.05% 
Lobular carcinoma 2 2.10% 
Malignant Phylloides 1 1.05% 
Lobular + Ductal 
component 
2 2.10% 
Fibrous Histiocytoma 1 1.05% 
Colloid carcinoma 1 1.05% 
Medullary carcinoma 3 3.14% 
Pagets  1 1.05% 
The risk of primary breast cancer in contra lateral breast is significant. 
approximately 1% per year.Patients younger than 55 years at the time of diagnosis 
or lobular histology appear to increase this risk to 1.5%. 
In our study, 
 One patient with malignant fibrous histiocytoma presented with lung metastasis. 
All the other patients who developed metastasis are of invasive ductal carcinoma 
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HISTOLOGICAL GRADE OF TUMOR 
• Grade is classified as I, II, III on the basis of tubule formation, nuclear 
pleomorphism and mitotic rate as per bloom and Richardson classification. 
• In our study. 
GRADE NUMBER PERCENTAGE 
I 42 53 
II 32 35 
III 10 12 
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53%
35%
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III
 
  
10 patients are of histological grade III of which 3 developed local recurrence  
 2 developed lung secondarius during follow up 
 1 developed spinal metastasis 
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RECEPTOR STUDIES 
 
ER/PR Receptor Studies was done for 18 patients who were affordable. 
 It was positive in all postmenopausal patients – 12 
  3 Premenopausal patients  
  They were given Tamoxifen 
  ER-Negative Receptor Studies noted in 3  Premenopausal  
patients. 
  They were given combination chemotherapy.  
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NOTTINGHAM PROGNOSTIC INDEX 
T Size (cms) x 0.2    +Lymphnode stage (1 – 3) + Histological grade (1-3) 
    1 – No Node 
    2 – up to 3 Node 
    3 - > 3 Node 
 
NPI Prognosis
 
15 years survival
 
<3 Good 80% 
3.1 – 5.4 Moderate 42% 
>5.4 Poor 13% 
 
In our study  
  NPI   No. of Patients 
  <3    8 
  3.1 – 5.4   55 
  > 5.4    32 
During follow up it was detected out of this 32 patients with NPI >5.4, 5 had local 
recurrence, 3 had lung metastasis, 2 spine  metastasis, 1 brain metastasis, 2 had 
supraclavicular node involvement.  
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INVESTIGATION 
 In our study all the patients were subjected to routine investigation like 
urine albumin, sugar, blood urea sugar, Sr. creatinine, x ray chest, Fine needle 
Aspiration cytology, ultra sound abdomen. 
 
 Mammogram of opposite breast was done in all locally advanced breast 
cancers. 33 patients underwent mammogram and were found to be normal. 
 CT chest, pleural aspiration cytology was done for 2 patients who presented 
with lung secondaries USG abdomen, x ray of long bones and vertebrae taken to 
exclude other metastasis. 
 
 CT. dorsolumbar spine was done in one  patient who had collapse of D6 
vertebra for which local radiotherapy was given. 
 
 CT brain was done in one patient who presented with headache, Seizures 
which showed metastatic deposites in cerebellar hemisphere. She developed raised 
intracranial tension for which ventriculoperitioneal shunt was done. 
 
CT abdomen was done in patients with Ascites who had multiple liver 
secondaries. Paracentesis was done and malignant deposists detected in 
cytological analysis.  
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MANAGEMENT 
After confirming the diagnosis staging was done by TNM classification 
most of the cases with stage I and II were subjected to modified radical 
mastectomy, simple mastectomy with or without axillary dissection was done for 
stage III and IV. Adjuvant chemotherapy and hormone therapy was given to most 
of the patients. Locally advanced cancer patients received radiotherapy. Patients 
with Brain and spinal metastasis received loco regional radiation.  
TYPE OF SURGERY 
NO : OF 
PATIENTS 
PERCENTAGE
Simple mastectomy 14 15 
Simple mastectomy with axillary sampling / 
clearance 
11 13 
Modified radical mastectomy 59 67 
Toilet mastectomy 5 5 
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LYMPHNODE WITH METASTATIC DEPOSITS IN RESECTED 
SPECIMEN 
 
31%
27%
29%
13%
NO NODES
2 NODES
2-6 NODES
>6
 
 
In our study minimum of three to maximum of Twentytwo lymphnodes were 
found in resected specimen among which. 
• No metastatic deposits were found in 20 patients (31 %) 
• 2 nodes positive for deposits in 17 patients. (27%) 
• 2-6 nodes were positive for deposits in 19 patients. (29%) 
• More than 6 nodes were positive for deposits in 13 patients. (13%)  
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RESECTED MARGINS 
• In our study 
• Positive resection margins were found in 17 patients they were given 
radiotherapy 3 of them developed local recurrence. 2 developed metastasis one 
in lung, one in brain.  
 
ADJUVANT THERAPY: 
 Chemotherapy with CMF given to all stage III B 
Patients – 33 
Patients with more than 3 nodes received Chemotherapy- 12 patients 
Patients presenting with metastatic disease received chemotherapy – 4 patients 
Tamoxifen given to all postmenopausal patients-47 
RADIOTHERAPY 
• Adjuvant radiotherapy was given to patients whose Tumor size is more than 5 
cm or with four or more clinically positive axillary lymphnodes or who have 
positive resection margins after surgery. 
• Tumor size more than 5cm  -  64 patients 
• Positive resection margins found in 17 patients 
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FOLLOW UP 
 
 
 All the patients were followed up with clinical examination at monthly 
interval and with blood count and biochemistry, ultrasound abdomen, 
Mammography at 3 monthly interval. 
 Follow up period were from 6 months to 20 months. 
 76 out of 95 patients came for regular follow up (80%)  
 In our study, 7 were detected to have local recurrence. They were treated 
with Radiotherapy and chemotherapy. 
8 developed   distant metastais  
Lung secondaries  - 4 
Brain secondaries - 1 
Spine metastasis   - 2 
Liver metastasis    -1 
They were given chemotherapy . 
CT chest, pleural aspiration cytology for confirmation of malignant deposits done 
in patients  with lung secondaries and pleural effusion  
CT Dorsolumbar spine done in patients with spine metastasis one had D6 vertebra 
compression and local radiation was given  
CT brain was done in the patients with brain metastasis and one developed raisied 
intracranial pressure for which ventriculoperitoneal shunt was done. 
CT abdomen was done in patient with liver metastasis, who had Ascites. 
Paracentesis of Ascitic fluid was done and malignant cells were detected in 
cytological analysis. 
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SUMMARY 
• In our study the following observations were made.  
1. The commonest age of presentation was 40 – 50 years of age. 
2. About 47.36 were premenopausal and 46.31 were postmenopausal 5.26% were 
Nullipara. 
3. Commonest mode of presentation was painless lump in 46.31%. 
4. Most of the patients presented with stage III  disease 62.09%. 
5. Lymphnode positivity during presentation was about 69.46%. 
6. Invasive ductal carcinoma was the commonest pathological variety in our 
stage. Histological grade I was found in 56.84%. 
7. Most of our patients presented with Tumor size more than 5 cm (67.36%).  
8. Modified Radical mastectomy was done in 59 patients simple mastectomy with 
axillary clearance in 11 patients.  
9. Resected margins were found to be positive in 17 patients all of them were 
given radiotherapy. Three of them developed locoregional recurrence 2 
developed metastasis. One in lung, one in brain.  
10. Lymphnode examination for metastatic deposits in pathological specimen 
showed positivity in 49 patients. More than 6 nodes were positive for 
metastatic deposits in 13 patients. Of which 4 developed locoregional 
recurrence and one developed liver, lung metastasis. One patient with 
supraclavicular node developed spine metastasis.  All patients were treated 
with chemotherapy and radiotherapy.  
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11. Histologic grade 1 found in 44.21 of patients, grade 3 found in 10.52% of our 
patients (10 Pts) of which 3 had locoregional recurrence.  2 developed lung 
secondaries during the follow up period.  
12. 4 patients who developed lung metastasis had Tumor size more than 8cm 
during presentation and 1 of them had histological grade III invasive ductal 
carcinoma. Supraclavicular node was involved in one patient.  
13. One patient with brain metastasis had Tumor size of 6 cm during presentation, 
she had more than 6 nodes positive for deposits in pathological resection 
specimen.   
14. One patient who developed both spine and liver metastasis presented with 
tumor involving all quadrants. 
15. Nottingham Prognostic index was found to have direct correlation with   
     prognosis in our study. In 32 of our patients with NPI more than 5.4, 5 had   
     local   
     recurrence, 3 had lung metastasis, 2 developed spine metastasis and one  
    developed brain metastasis during follow up.     
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CONCLUSION 
 The aim of the study is to identify the prognostic factors in primary breast 
cancer. The utility of prognostic factors lies not only in their ability to 
prognosticate the outcome of the disease but also in detecting early disease, 
monitoring of disease course, screening for recurrent disease. They also help in 
deciding upon application of adjuvant systemic therapy and in identifying patients 
of poor prognosis who warrant more aggressive investigational therapies. 
 Commonly assessed prognostic factors are number of lymphnodes in axilla, 
tumour size, TNM stage, histologic tumour type, histologic tumor grade. Sex 
steroid receptor study not done for all patients since it is not available in our 
institution. 
 Tumor size has linear relationship with prognosis and eventual metastasis. 
As tumor size increased, survival decreased regardless of lymphnode status and as 
lymphnode involvement increased, survival status decreased regardless of tumor 
size. Medial lesions have slightly worse prognosis than lateral lesions due to 
involvement of mammary nodes. Histological grade of tumor also seems to 
correlate with regional recurrence and metastasis Patients with post operative 
positive resection margins were also at high risk of locoregioal recurrence. 
 Hence it is suggested that for patients with breast cancer, the prognostic markers 
that can be routinely assessed are axillary lymphnode status, tumour size,  
histologic grade, estrogen receptor status, post operative findings like positive 
margins. They are helpful in planning adjuvant treatment. 
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Name:      Age:    IPNO: 
 
ADDRESS:         DOA 
 
 
HISTORY 
 
Lump 
 
Duration 
 
Pain 
 
Discharge 
 
Ulcer 
 
Others 
 
Axillary Node 
 
 
Metastasis  
 
REPRODUCTIVE  HISTORY 
 
Age at Menarche   : 
 
Age at First Child Birth  : 
 
Parity     : 
 
Duration of breast feeding  : 
 
Menstrual Status   : 
 
Hormonal Therapy   : 
 
FAMILY HISTORY 
 
Number of Relative affected : 
 
Other Co. existing Malignacy : 
 
Age at which Cancer Detected : 
 
Laterality    : 
 
TREATMENT HISTORY 
 
Previous Benign Diseases  : 
 
Previous Malignsnt Disease : 
 
PHYSICAL EXAM 
 
BREAST MASS: 
 
Size     : 
 
Location    : 
 
Consistency    : 
 
Fixity     : 
 
SKIN CHANGES: 
 
Erythema    :   Dimpling : 
 
Edema/Peud – e-orange  :   Satellite nodules : 
 
NIPPLE CHANGES  
 
Retraction    :   Eversion : 
 
Discoloration    :   Discharge : 
 
AXILLARY NODE  
 
Number    :   Fixity  : 
 
Location    : 
 
Supraclavicular Node 
 
Opp. Breast & Axilla 
 
Abdomen 
 
Respiratory system 
 
Spine & Cranium 
 
P/R & P/V 
 
Stage: 
 
 
Investigations 
 
1. FNAC 
2. X-Ray Chest 
3. Mammogram 
4. USG abdomen 
5. CT. Thorax 
6. LFT 
7. Others X-Ray long bones         
 Bone Scan 
 
 
Surgery 
 
 
HPE REPORT  
 
Type of Malignancy  : 
 
Grade    :  
 
Resected Margin  :  
 
Lymphnode Status  : 
 
Receptor Status  : 
 
CHEMOTHERAPY 
 
RADIOTHERAPY 
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MULTIPLE METASTASIS TO THE BRAIN 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CANCER EN-CUIRASSE 
 
 
 
PAGET'S DISEASE OF THE NIPPLE 
 
 
 
 
PEU DE ORANGE 
 
 
 
LUMP 
 
 
 
 
ULCERATIVE GROWTH  
 
 
 
 
LUMP 
 
 
 
 
 
 
 
DCIS 
 
 
 
 
 
 
LCIS 
 
 
 
 
 
 
 
IDC / LOBULAR 
 
 
INVASIVE LOBULAR 
 
 
MEDULLARY CARCINOMA 
 
 
 
 PAGETS 
 
 
 
 
 
PHYLLOIDES 
 
 
NP I
Type Grade Lymphode Margins Local Metastas
i
1
Arokiamary 
912968 40
Pre
4
Lump
R U.Outer
Nil
5x4cm Single II b
MRM IDC
I
Negative free
3
2
Muniyammal 
910782 63
Menopause
3
Lump
L U.Outer
Nil
6x5cm Single III b
MRM IDC
I
One/6 free
4.2
3
Devaki 919850
45
Hyst
3
Lump
R U.Outer
Nil
5x4cm Single II b
MRM IDC
I
Negative free
3
4
Punitha 920025
47
Pre
2
Lump
L U.Outer
Nil
4x5cm Single II b
MRM IDC
gradel
4/6+ve free
5
5
Lakshmi 918798
43
Menopause
2
Lump,Ulcer,dis
charge R All
Nil
8x7 Single III b
Simple IDC
I
Lung
4.6
6
Saroja 885614
50
Menopause
2
Lump
R U.Outer
Nil
6x4cm Single III A 
MRM IDC
II
2/6+ve
5.2
7
pitchaiammal 
918124 41
Pre
Null
Lump,pain,disc
harge L Central
Nil
10x8cm Single III A 
MRM IDC
I
3/6 +ve Involved
5
8
Chandra 916618
60
Menopause
6
Lump
R U.Outer
Nil
6x5cm Nil III b
MRM IDC
I
1/6+ve
3.2
9
Anjamal
50
Menopause
4
Lump
R U.Outer
Nil
6x3cm Nil II b 
MRM IDC
I
7/7+ve free
3.2
10
Rajeshwari
52
Hyst
2
Lump,pain
R U.Outer
Nil
3x2cm Nil II A
MRM IDC
I
4/6-ve free
2.6
11
Maragatham 
915255 55
Menopause
3
Lump
R U.Outer
Nil
8x7cm 2 III b
Simple M IDC
II
free
6.6
12
Mariyayee 
912413 55
Menopause
4
Lump,pain,disc
harge R Areola
Nil
2x1cm 1 II A
MRM IDC
II
6/6+ve Involved
3.4
13
Geetha911685
45
Pre
Null
Lump,pain,disc
harge R All
Aty pical 
hyperpla 14x10cm 3 III b
Simple M IDC
III
Involved L.R
7.8
14
Eashwari 
38
Menstruating
2
Lump
L U.Outer
Nil
3x2cm Single II b
MRM IDC
I
3/6+ve free
3.6
15
Senthamarai
60
Hyst
3
Lump
R U.Outer
Nil
6x5cm 2 III A 
MRM IDC
II
7/7+ve free
6.2
16
Vishalakshi
50
Menopause
3
Lump
R Central
Nil
6x6 cm 1 III A 
MRM IDC
I
5/7 +ve
5.2
17
Lakshmi 841372
50
Menopause
2
Lump
R U.Outer
Nil
4x4 cm Nil III A 
MRM IDC
I
Negative free
2.8
18
Valarmathy
35
Pre
2
Lump
R U.Outer
Nil
7x8 cm Nil III b
MRM IDC
I
Negative free
3.6
19
Masilamani
48
Pre
1
Lump
R U,L Outer
Aty pical 
hyperpla 8x6 cm 2 III b
Simple M IDC
II
free
6.6
20
Malarazhagi 
927823 45
Pre
2
Lump
L Central
Nil
5x3 cm 1 III A
MRM IDC
II
4/6+ve free
6
21
Prema 928032
50
Menopause
2
Lump
L U,L Outer
Nil
15x10 cm 1 III A
MRM IDC
I
5/7+ve
7
22
Thiruvarangam 
935443 55
Menopause
3
Lump
R All
Nil
15x10 cm 3 III A
MRM IDC
I
4/6+ve
7
23
Dhanam 
65
Menopause
3
Lump, Pain
L U, Outer
Nil
3x4cm Nil II A
MRM IDC
I
free
2.8
24
Chandrakala 
929317 45
Menopause
Null
Lump, Pain
R L.inner
Nil
2x1cm 3 II A
MRM IDC
I
6/6+ve free
4.4
Stage
Parity Presentation Silte Quadrant
Followup
Name Sno
Menstrual 
Satus
Surgery HistologyBenign 
diseae
Tumour 
size
Node
25
Suseela 924972
50
Menopause
2
Lump
L U.Outer
Nil
10x10cm Nil III b
MRM IDC.Nos
g.I
6/6+ve
5
26
Lakshmi 928996
45
Menopause
2
Lump
L Central
Nil
10x8cm 2 III b
Simple.M IDC
II
free
7
27
Dhanabakiyam 
932227 70
Menopause
3
Lump, Pain
L U.Outer
Nil
3x5cm 1 II b
MRM IDC.Nos
I
Negative free
3
28
Selvi
32
Menstruating
2
Lump
L U.Outer
Nil
12x5cm 2 III b
MRM IDC.Nos
II
7/7+ve free
7.4
29
Indrani
60
Menopause
3
Lump
L U.Outer
Nil
6x4cm 1 III A
MRM IDC
II
2/4+ve free
5.2
30
Vasanthi
40
Pre
2
Lump
R Central
Nil
4x5cm 1 III b
Simple IDC
II
free
4.8
31
Amsadevi
35
Pre
2
Lump
L U.Outer
Nil
8x6 cm 2 III b
MRM IDC.Nos
I
Negative free
3.6
32
Pushpam
37
Pre
2
Lump
L U.Outer
Nil
6x5cm Nil III b
S.M+A.D IDC.Nos
I
1/6+ve free
3.2
33
Manickam 90095
58
Post. Meno
2
Lump
R U.inner,L.inner
Nil
15x10 cm 2 III b
Simple.M IDC
I
Involved L.Node opp 
axilla+ve 6
34
Kannambal 
905179 55
Menopause
3
Lump
R
U.Outer,L.Outer
,           L.inner
Nil
10x8cm 2 III c
Toilet.M IDC
III
2 (2/22)+ve Involved S.Cnode Involved
7
35
Lakshmi
52
Menopause
3
Lump, Pain
R U.Outer
Nil
5x8cm 2 III A
MRM IDC
I
3/8+ve free
4.6
36
Selvi
24
Menstruating
2
Lump,discharg
e R U.Outer
Nil
6x4cm 1 II b
simple IDC/Nos
I
Involved
4.2
37
Vedambal 
901993 40
Menopause
2
Lump, Pain
R U.Outer
Nil
10x8cm 2 III b
simple IDC
I
positive opp 
axilla+ve 5
38
Malarkodi 
917872 47
Hyst
3
Lump, Pain
R U.Outer
Nil
7x7cm 1 III A
MRM IDC
I
4/6+ve Involved
5.4
39
Pattu 869995
60
Menopause
3
Lump, Pain
L U.Outer
Nil
8x5cm 1 III A
MRM IDC
II
3/6+ve free
5.6
40
Meenambal 
139106 42
Pre
3
Lump, Pain
R U.Outer
Nil
3x2cm 1 II A
MRM IDC
II
6/10+ve free
4.6
41
Selvam
60
Menopause
3
Lump, Pain
R U.Outer
Nil
6x5cm 3 III A
MRM IDC
III
2 (2/22)+ve free
6.2
42
Kunjammal
60
Menopause
3
Lump, Pain
L U.Outer
Nil
3x2cm 1 II b
MRM IDC
II
1/6+ve free
4.6
43
Rajammal
50
Menopause
3
Lump, Pain 
node L All
Nil
15x10 cm 3 III A
MRM IDC
III
3/10+ve free
8
44
Vijayalakshmi
55
Menopause
2
Lump, Pain
R U.Outer
Nil
8x7cm single III b
MRM IDC
II
3/7+ve free
5.6
45
Vasantha 869990
35
Pre
2
Lump
L U.Outer
Nil
4x5cm 1 III A
Simple IDC/Nos
II
free
4.8
46
Papathy
40
Pre
3
Lump
R All
Nil
8x5cm 2 III A
MRM IDC
I
Negative free
3.6
47
Janaki
52
Menopause
3
Lump, 
ulcer,discharge L U.Outer
Nil
10x8cm 3 III b
Toilet.M IDC
III
Involved
6
48
Violet Mary
42
Pre
3
Lump
L U.Outer
Nil
6x3cm 1 III A
MRM IDC
II
3/6+ve free
5.2
49
Vasantha 
45
Pre
2
Lump
R U.Outer
Nil
5x3 cm 1 III b
MRM IDC
I
4/6+ve free
5
50
Sabinabeevi
50
Menopause
2
Lump
R Central
Nil
3x4cm Nil III A
MRM IDC
I
1/5+ve free
2.6
51
Adikala Mary
45
Menopause
2
Lump 
L U.Outer
Nil
3x2cm 1 II b
MRM IDC
II
6/6-ve free
3.6
52
Mukkayee
51
Menopause
3
Lump
L U.Outer
Nil
10x8cm 2 II b
Toilet.M IDC/Nos
II
4/6 +ve free
7
53
Vallinayakam
45
Pre
3
Lump
R U.Outer
Nil
5x2cm Nil III b
S.M+A.D IDC/Nos
II
Negative free
4
54
Baby
27
Menstruating
2
Lump
L U.Outer
F.adeno
ma 5x4cm Nil II b
MRM IDC
II
Negative free
4
55
Muthu Rakku
46
Pre
3
Lump
R U.Outer
Nil
5x6cm Nil II b
MRM IDC
II
6/6+ve free
5,2
56
Manjula
45
Pre
2
Lump
R U.Outer
Nil
6x3cm 1 III A
MRM IDC/Nos
II
10/16+ve free
6,2
57
Chandra
60
Menopause
6
Lump
R U.Outer
Nil
8x5cm III b
MRM IDC
I
Negative free
3,6
58
Valli
45
Pre
3
Lump
R I.Lower
Nil
6x5cm 1 III b
S.M+A.D IDC/Nos
III
4/6+ve S.C+ve
7,2
59
Jeya Mary
57
Menopause
5
Lump, Pain
L I.Lower
Nil
8x5cm 1 III A
MRM IDC
I
3/5+ve free
4.6
60
Jameela beevi
60
Menopause
Nulli
Lump, 
Pain,ulcer,disc R U.Outer Central
A.Hyper
plasia 6x4cm 2 III b
Toilet.M IDC
III
involved Lung
6.2
61
Boopathy
35
Menstruating
2
Lump
L U.Outer
Nil
3x2cm 1 II b
MRM IDC
II
Negative Negative
3,6
62
Suseela 
43
Pre
2
Lump
L U.Outer
Nil
4x2cm 1 II b
S.M+A.D IDC
I
3/3+ve involved
3.8
63
Dhavamani
35
Menstruating
2
Lump
L U.Outer
Nil
6x5cm 1 III A
MRM IDC/Nos
I
1/4+ve involved
4.2
64
Padmavathy
45
Pre
2
Lump
R U.Outer
Nil
4x2cm II A
MRM IDC/Nos
II
6/12+ve free
4,8
65
Rajeshwari
50
Pre
2
Lump
R U.Outer
Nil
5x3 cm 1 II b
MRM IDC
I
1/6+ve free
4
66
Kalaiselvi
38
Menstruating
2
Lump, 
Pain,discharge L All
Fibro 
adenosi 8x9cm 2 III b
S.M+A.D IDC
II
6/7+ve involved
6,6
67
Revathy
37
Menstruating
2
Lump
R U.Outer
Nil
6x4cm 1 III b
MRM IDC
I
1/6+ve free
4.2
68
Seeniyammal
50
Menopause
2
Lump
L U.Outer
Nil
3x2cm 1 II b
MRM IDC
I
2/6+ve free
3.6
69
Subu laskshmi
44
Pre
2
Lump
R U.Outer
fiber 
adenom 7x6cm II b
MRM IDC
II
Negative free
4,4
70
Jothi
39
Pre
3
Lump
L U.Outer
Nil
5x3 cm 1 II b
MRM IDC/Nos
I
3/6+ve involved
4
71
Lakshmananan
65
Male
3
Lump
R U.Outer,inner,central 10x8cm 2 III b
MRM IDC
II
3/6+ve free
6
72
Lakshmi
45
Menopause
3
Lump, node
L U.Outer central
Nil
12x8cm 1 III b
Toilet.M IDC
III
Involved Local 
recurenc
spine
7.4
73
Balammal
65
Menopause
3
Lump, Pain
R L.inner
Nil
8x5cm 3 III a
chemo IDC
II
Lung
5.6
74
Jeyamari
45
Menopause
Nulli
Lump
L U.Outer
Fibroad
enoma 2x5cm 1 II b
MRM IDC
I
Negative Negative
3
75
Kumudham
60
Menopause
6
Lump, Pain 
disaharge L U.Outer
Nil
8x5cm 1 III b
MRM Colloid Negative Negative
2,6
76
Daisy Rani
43
Pre
2
Lump, 
headache R Central
Nil
6x4cm III b
S.M+A.D IDC
II
6/7+ve Involved Local + Brain
5.2
77
Alamelu
40
Menopause
4
Lump, 
discharge R U.inner,L.inner
Nil
10x8cm 4 III b
chemo IDC
I
opp-
axilla + 7
78
lakshmi 935750
50
Menopause
2
NoLump, 
discharge R Nolump
Nil
       - 1 Cainsitu
MRM Pagts 1/6 +v  -ve
1
79
Vasantha
50
Menopause
2
Lump
R U.Outer
Nil
 2 X 1              - II A
MRM IDC/Lob
ularca II
  -Ve  -ve
3.4
80
Hanifa
55
Menopause
1
Lump
L U.Outer
Nil
 3 X 3              - II A
S.M.+A.D 
Chemo 
Lobular
ca
 10/10 -ve  -ve
1.6
81
Amsavalli
32
Menstruating
2
Headache, 
blurring, L Central
Nil
8 X 4 3 IV
S.M.done 
3 yrs break 
IDC
II
Local Brain 
Bone 5.6
82
Boopathy
45
Pre
2
Lump, Pain
L U.Outer
Fibroad
enosis  8 X 4 1 III A
Simple.M IDC
III
Involved Local 
Recuren 6.6
83
Tamilarasie
42
Pre
4
Lump
R U.Outer
Nil
 8 X 3 1 III B
Simple.M IDC
II
Involved
5.6
84
Kamalaa
58
Menopause
2
Lump, Pain
L U.Outer
Nil
 3 X 2 3 II A
MRM Lobular/
Ductal
6/6 + ve Free Local 
Recuren 5,6
85
Pandi devi 
47
Menopause
2
Lump, Pain
R All
Nil
 10 X 7 2 III B
S.M+A.D IDC
I
1/11 +ve Free Bilat 
S.C/L.C
spine,Liv
er, Brain 5
86
Fathima
53
Menopause
3
Lump, Pain 
R All
Nil
8 x 5 2 IV
MRM done 
21/2 yr 
IDc/Nos
III
6/6 +ve Free Lung
4,6
87
Kalaiselvi
35
Menstruating
3
Lump
L U.Outer
fiborad 
enosis 8 X 4 1 III B
MRM Atypical 
Medullar
4/6+ve Free
4,6
88
Viji
30
Menstruating
3
Lump
R U.Outer
Fibroad
enosis 5 X 4              - II B
Simple.M Dcis  -ve Free
3
89
Nebeesha 
begum 40
Pre
3
Lump
L U.Outer
Nil
6 X 5 1 III A
S.M+A.D Medullar
y ca
3/4 +ve Free
3.2
90
Suseela
40
Menstruating
2
Lump, Pain
R U.Outer
_
8 X 2 2 II B
S.M+A.D IDc
II
5/5 +ve Free
5,6
91
Valarmathy
40
Menstruating
4
Lump, Pain
L U.Outer
Nil
8 X 7 1 III A
S.M+A.D Medullar
y ca
5/5 +ve Free
4,6
92
Satynathan
31              
Lump, Pain
R U.Outer
Nil
6 X 5 1 IV
Chemo M F H Local 
Recurrr 
Lung 
3.2
93
Subbulakshmi
48
Menopause
3
Lump, Pain 
Dysnea R All
Nil
20 X 14 1 III B
Simple.M IDC
II
Free
8
94
Valarmathy
43
Pre
3
Lump, 
discharge R U.Outer inner ce
_
12 X 8 3 III B
S.M+A.D Lobular  -ve  -ve
3,4
95
Ayeshammal
55
Menopause
3
Lump, Pain 
dyspnea R U.Outer
Nil
6 X 5 1 IV
Chemo IDc
I
Lung
3.2
Pre - Pre Menstrual Patients 
Hyst - Hystrectomy 76, 81,92,95-presented with Metastasis
U.O - Upper Outer 72,85-Developed spine Metastasis
MRM - Modified Radical Mastectomy 85-Developed Liver, Brain Metastasis 
Simple.M - Simple Mastectomy 5,60,73,86- Developed Lung Metastasis
S.M + A.D - Simple Mastectomy + Axillary Dissection
LR - Local Recurrence
IDC - Intraductal Cavinoma
IDC/NOS - Intraductal  Cavinoma - Not Otherwise Specifed  
S.C Node - Supraclavicular node
NPI - Nottingham Prognostic Index
